The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 377-385

  Nakamura, Tomoki ^a,b   Grimer, Robert ^a   Gaston, Czar ^a   Francis, Matthew ^c   Charman, Jackie ^c   Graunt, Piers ^c   Uchida, Astumasa ^b   Sudo, Akihiro ^b   Jeys, Lee ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

C reactive protein; Charlson index score; Comorbidity; High grade tumour; Soft tissue sarcoma

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM; SOFT TISSUE SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872119503     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.004     Document Type: Article

References (36)

1. A. Stojadinovic, D.H.Y. Leung, and A. Hoos Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcoma Ann Surg 235 2002 424 434
2. P.D. Stefannovski, E. Bido, and A.D. Paoli Prognostic factors in soft tissue sarcomas: a study of 395 patients Eur J Surg Oncol 28 2002 153 164
3. M.W. Kattan, D.H. Leung, and M.F. Brennan Postoperative nomogram for 12-year sarcoma-specific death J Clin Oncol 20 3 2002 791 796
4. P.I. Karakiewicz, G.C. Hutterer, and Q.D. Trinh C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. A European study of 313 patients Cancer 110 2007 1241 1247
5. D.K. Kim, S.Y. Oh, and H.C. Kwon Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer BMC Cancer 9 2009 155
6. B.L. Pierce, R. Ballard-Barbash, and L. Bernstein Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients J Clin Oncol 27 2009 3437 3444
7. D.C. McMillian, K. Canna, and C.S. McArdle Systemic inflammatory response predicts survival following curative resection of colorectal cancer Br J Surg 90 2003 215 219
8. H.R. Scott, C. McMillan, and L.M. Forrest The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer Br J Cancer 87 2002 264 267
9. M. Alifano, P.E. Falcoz, and V. Seegers Pretreatment serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer J Thorac Cardiovasc Surg 142 2011 1161 1167
10. J.R. Stark, Haojie Li, and P. Kraft Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality Int J Cancer 124 2009 2683 2689
11. J. De Mello, L. Struthers, R. Turner, E.H. Cooper, and G.R. Giles Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer Br J Cancer 48 1983 341 348
12. J.S. Falconer, K.C. Fearson, and J.A. Ross Acute-phase protein response and survival duration of patients with pancreatic cancer Cancer 75 1995 2077 2082
13. T. Nazoe, H. Saeki, and K. Sugimachi Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma Am J Surg 182 2001 197 201
14. J.R. Ouellette, D.G. Small, and P.M. Termuhlen Evaluation of Charlson-age comorbidity index as predictor of morbidity and mortality in patients with colorectal carcinoma J Gastrointest Surg 8 2004 1061 1067
15. B. Singh, M. Bhaya, and J. Stern Valiation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institution study Laryngoscope 107 1997 1469 1475
16. O. Birim, A.P. Kappetein, and A.J. Bogers Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer Eur J Cardiothorac Surg 28 2005 759 762
17. T.M. Koppie, A.M. Serio, and A.J. Vuckers Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer Cancer 112 2008 2384 2392
18. D. Santos Arrontes, M.J. Fernandez Acenero, J.I. Garcia Gonzalez, M. Martin Munoz, and P. Paniagua Andres Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index J Urol 179 2008 857 861
19. M.S. Tetsche, C. Dethlefsen, L. Pedersen, H. Sorensen, and M. Norgaar The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study BMC Cancer 8 2008 31
20. H. Nakanishi, N. Araki, and I. Kudawara Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma Int J Cancer 99 2002 167 170
21. T. Nakamura, A. Matsumine, T. Matsubara, K. Asanuma, A. Uchida, and A. Sudo Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma Cancer 118 2012 1055 1061
22. R. Grimer, N. Athanasou, and C. Gerrand UK guidelines for the management of bone sarcomas Sarcoma 2010 2010 317462
23. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. Mackenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. (7th ed). New York, NY: Springer; 2010.
25. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
26. G. Mantovani, A. Macciò, and M. Pisano Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patients autologous PBMCs are capable of releasing high amounts of various cytokines Int J Cancer 71 5 1997 724 731
27. S. Ramsey, G.W.A. Lamb, M. Aitchison, and D.C. McMillan The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer Br J Cancer 95 2006 1076 1080
28. J.V. Castell, M.J. Gomez-Lechon, M. David, R. Fabra, R. Trullenque, and P.C. Heinrich Acute-phase response of human hepatocytes; regulation of acute-phase protein synthesis by interleukin-6 Hepatology 12 1990 1179 1186
29. T. Nazoe, D. Korenaga, and M. Futatsugi Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor maker Cancer Lett 192 2003 89 95
30. P. Rutkowski, J. Kaminska, M. Kowalska, W. Ruka, and J. Steffen Cytokine serum levels in soft tissue sarcoma patients: correlations with clinoco-pathological features and prognosis Int J Cancer 100 2002 463 471
31. S.J. Wigmore, K.C. Fearon, and K. Sangster Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer Int J Oncol 21 2002 881 886
32. S.S. Tabibzadeh, D. Poubouridis, L.T. May, and P.B. Sehgal Interleukin-6 immunoreactivity in human tumors Am J Pathol 135 1989 427 433
33. D.J. Brull, N. Serrano, and F. Zito Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease Arterioscler Thromb Vasc Biol 23 2003 2063 2069
34. G. Kressel, B. Trunz, and A. Bub Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk Atherosclerosis 202 2009 263 271
35. A.G. Betroni, G.L. Burke, and J.A. Owusu Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA) Diabetes Care 33 2010 804 810
36. R. Yancik Cancer burden in the aged: an epidemiologic and demographic overreview Cancer 80 1997 1273 1283